Co-founder

genei

Innovative AI platform combining computational biology and machine learning for next-generation solutions.

Visit Website
Founded: 2022
genei

genei is revolutionizing how researchers and knowledge workers interact with information. As Co-founder, I helped develop an AI research assistant that dramatically reduces the time needed to read, understand, and synthesize information from academic papers, reports, and other documents.

The platform uses advanced natural language processing and machine learning to automatically summarize content, extract key insights, and help users find connections between different sources. This technology is particularly valuable for researchers, students, and professionals who need to process large volumes of information efficiently.

Key Achievements

  • Created an AI platform that reduces research time by up to 80%
  • Developed proprietary summarization algorithms
  • Built a growing user base across academic and professional sectors
  • Secured funding from leading AI and education technology investors

genei represents the application of AI to solve fundamental productivity challenges in knowledge work, demonstrating the potential for technology to augment human capabilities in research and writing.

Key Achievements

Created an AI platform that reduces research time by up to 80%

Developed proprietary summarization algorithms

Built a growing user base across academic and professional sectors

Secured funding from leading AI and education technology investors

Leadership Team

Billy Richards

Billy Richards

Co-founder

Alex Thompson

Alex Thompson

CEO & Co-founder

Lisa Zhang

Lisa Zhang

Head of Product

Interested in Learning More?

If you'd like to learn more about genei or explore potential collaboration opportunities, I'd love to connect.

Other Ventures

Changeblock

The world's first purpose-built environmental assets exchange, revolutionizing climate finance and carbon markets.

Learn more

HaloVerify

AI-driven NLP solutions for regulated healthcare and diagnostics, with a successful exit before age 25.

Learn more